DexCom, Inc. vs iShares Russell 2000 ETF — how do they compare? DexCom, Inc. trades at $90.52 (market cap $33.79B), while iShares Russell 2000 ETF trades at $302.88. Which is the better fit depends on your goals.
| DXCM | IWM | |
|---|---|---|
Market Cap | $33.79B | — |
Sector | Health | — |
52-Week High | $89.53 | $301.69 |
52-Week Low | $54.84 | $225.45 |
Enterprise Value | $33.24B | — |
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $90.23, up 2.94% today and near its 52-week high, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $0.70 versus $0.61 expected, and raised full-year guidance. Revenue growth remains robust at 13% year-over-year, supported by G7 system adoption and international expansion. Profit margins improved, with net income margin reaching 20.12% in 2025. Analyst sentiment is overwhelmingly positive, with 80% buy ratings.
The outlook for DXCM is favorable due to sustained demand for continuous glucose monitors and strategic initiatives like 'Road to 100'. Key risks include competitive pressures, regulatory scrutiny, and valuation multiples above industry averages. The stock's current price is slightly above the consensus target of $88.65, suggesting near-term consolidation may occur before further upside.
IWM, the iShares Russell 2000 ETF tracking US small-cap stocks, trades at $302.33 with a 0.78% daily gain. Technical indicators show a bullish trend with strong moving average support, though RSI suggests potential overbought conditions. The ETF benefits from institutional preference due to its liquidity and options ecosystem, with recent news highlighting small-cap outperformance versus large caps in 2026.
Outlook remains positive as small caps lead market gains, but risks include higher volatility and competition from lower-cost alternatives. Institutional inflows and broadening market participation support further upside, though valuation concerns and economic sensitivity warrant monitoring.
Trailing returns across standard periods
Latest headlines on both assets
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →The ETF is designed to track the performance of the securities and the stocks in the Russell 2000 Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on IWM →